The AGE-RAGE Axis and RAGE Genetics in Chronic Obstructive Pulmonary Disease

Sharma, Alisha; Kaur, Sargeet; Sarkar, Malay; Sarin, B. C.; Changotra, Harish

doi:10.1007/s12016-020-08815-4

Cited by 43 publications

(32 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by Kashifa Ehsan et al Showed that plasma fibrinogen is a potential marker for disease severity in COPD using the GOLD and BODE index, which is similar to this study. Duvoix A et al concluded that fibrinogen is a valuable biomarker in patients of COPD, in particular for identifying those most prone to exacerbation, binds to important clinical endpoints, and acts as a surrogate marker for treatment achievement, similar to our current study 21 . In another small cohort of 96 Japanese people with milder COPD (median FEV1 predicted 70%), Higashimoto and colleagues institute that those with high blood levels of fibrinogen showed a negligible tendency to deteriorate lung function more rapidly (p = 0.054) 22 .…”

Section: Resultssupporting

confidence: 86%

Study of Levels of Plasma Fibrinogen and its Association with Disease Severity in Patients with Chronic Obstructive Pulmonary Disease

Masood¹,

Amin²,

Qasim³

et al. 2021

PJMHS

View full text Add to dashboard Cite

COPD has been recognized as a component of the systemic inflammatory syndrome. A commonly used indicator of the severity and progression of the disease in COPD is expiratory volume per second (FEV1). However, it is weakly associated with symptoms and administration difficulties in elderly patients. Therefore, there is a need for other markers that are better and easy to apply to sick and elderly patients. Plasma fibrinogen can be used as a marker of disease severity. Aim: To estimate the plasma fibrinogen level in patients with COPD and Relationship of levels of plasma fibrinogen with the severity of chronic obstructive pulmonary disease using the BODE classification and GOLD staging. Place and Duration: In the Medicine Unit-II of Jinnah Hospital Lahore for one-year duration from August 2020 to August 2021. Methods: In this cross-sectional study, 110 COPD patients were assessed by measuring plasma fibrinogen correlated with disease severity using the GOLD scale, BODE index and the 6-minute walk test. Results: Plasma fibrinogen is present in all COPD patients. A significant correlation was observed between the BODE index (r = 0.69, p <0.001), gold grading (r = 0.95, p <0.001) and plasma fibrinogen levels. Most of the 110 subjects (34.5%) were Grade II, then Grade III 30.9%, 18.1% Grade IV and 14.5% Grade I. In our study, it was found that the average level of fibrinogen increased with the increase in the GOLD stage, which was statistically significant, and the p value was 0.01. Conclusions: Plasma fibrinogen levels are significantly higher in COPD and can be used as a marker correlating with disease severity in COPD. Keywords: COPD; plasma fibrinogen; GOLDEN stage; BODE index.

show abstract

Section: Resultssupporting

confidence: 86%

Study of Levels of Plasma Fibrinogen and its Association with Disease Severity in Patients with Chronic Obstructive Pulmonary Disease

Masood¹,

Amin²,

Qasim³

et al. 2021

PJMHS

View full text Add to dashboard Cite

show abstract

“…AGER is a gene encoding Receptor for advanced glycation end-product (RAGE), and one of the ligands for RAGE is advanced glycosylation end-product (AGE), whose secretion is promoted by oxidative stress. The expression of RAGE and level of its ligands are enhanced in the lungs, mediating the inflammatory response in COPD [17,151,152]. Cigarette smoke extract induces the alteration of RAGE distribution via the activation of redox-sensitive damage-associated molecular pattern (DAMP) signaling through Nrf2 in cells, whereas the inhibition of RAGE exhibits anti-inflammatory and antioxidative/nitrosative effects through the inhibition of Nrf2/DAMP signaling [153].…”

Section: Oxidative Stress and Genetic Factorsmentioning

confidence: 99%

Reactive Oxygen Species and Antioxidative Defense in Chronic Obstructive Pulmonary Disease

et al. 2021

View full text Add to dashboard Cite

The respiratory system is continuously exposed to endogenous and exogenous oxidants. Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation of the airways, leading to the destruction of lung parenchyma (emphysema) and declining pulmonary function. It is increasingly obvious that reactive oxygen species (ROS) and reactive nitrogen species (RNS) contribute to the progression and amplification of the inflammatory responses related to this disease. First, we described the association between cigarette smoking, the most representative exogenous oxidant, and COPD and then presented the multiple pathophysiological aspects of ROS and antioxidative defense systems in the development and progression of COPD. Second, the relationship between nitric oxide system (endothelial) dysfunction and oxidative stress has been discussed. Third, we have provided data on the use of these biomarkers in the pathogenetic mechanisms involved in COPD and its progression and presented an overview of oxidative stress biomarkers having clinical applications in respiratory medicine, including those in exhaled breath, as per recent observations. Finally, we explained the findings of recent clinical and experimental studies evaluating the efficacy of antioxidative interventions for COPD. Future breakthroughs in antioxidative therapy may provide a promising therapeutic strategy for the prevention and treatment of COPD.

show abstract

“…AGEs have been extensively used as biomarkers for AGE-associated disorders such as diabetes mellitus, inflammation, and neurodegenerative diseases [ 49 , 50 , 51 ], and successful biomarker diagnosis plays a significant role regarding treatment decisions. AMI patients are at risk of AGE accumulation, and subsequent cell death is an essential factor in the development of their affliction [ 52 ].…”

Section: Resultsmentioning

confidence: 99%

CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial Infarction

Bayarsaikhan

et al. 2021

Antioxidants

View full text Add to dashboard Cite

Cardiovascular disorders, especially acute coronary syndromes, are among the leading causes of mortality worldwide, and advanced glycation end products (AGEs) are associated with cardiovascular disease and serve as biomarkers for diagnosis and prediction. In this study, we investigated the utility of AGEs as prognostic biomarkers for acute myocardial infarction (AMI). We measured AGEs in serum samples of AMI patients (N = 27) using the cupric ion reducing antioxidant capacity (CUPRAC) method on days 0, 2, 14, 30, and 90 after AMI, and the correlation of serum AGE concentration and post-AMI duration was determined using Spearman’s correlation analysis. Compared to total serum protein, the level of CUPRAC reactive AGEs was increased from 0.9 to 2.1 times between 0–90 days after AMI incident. Furthermore, the glycation pattern and Spearman’s correlation analysis revealed four dominant patterns of AGE concentration changes in AMI patients: stable AGE levels (straight line with no peak), continuous increase, single peak pattern, and multimodal pattern (two or more peaks). In conclusion, CUPRAC-reactive AGEs can be developed as a potential prognostic biomarker for AMI through long-term clinical studies.

show abstract

The AGE-RAGE Axis and RAGE Genetics in Chronic Obstructive Pulmonary Disease

Cited by 43 publications

References 120 publications

Study of Levels of Plasma Fibrinogen and its Association with Disease Severity in Patients with Chronic Obstructive Pulmonary Disease

Study of Levels of Plasma Fibrinogen and its Association with Disease Severity in Patients with Chronic Obstructive Pulmonary Disease

Reactive Oxygen Species and Antioxidative Defense in Chronic Obstructive Pulmonary Disease

CUPRAC-Reactive Advanced Glycation End Products as Prognostic Markers of Human Acute Myocardial Infarction

Contact Info

Product

Resources

About